Welcome to our dedicated page for Vivos news (Ticker: RDGL), a resource for investors and traders seeking the latest updates and insights on Vivos stock.
Vivos Inc. (OTCQB: RDGL) generates news centered on its development of radiotherapeutic devices and hydrogel-based technologies for oncology in both humans and animals. Company updates frequently highlight progress with its core platforms, RadioGel® for human use and IsoPet® for veterinary applications, which are designed to deliver targeted radiation directly to tumors while limiting exposure to healthy tissue.
Investors and observers following RDGL news will see detailed coverage of regulatory milestones for RadioGel, including Investigational Device Exemption (IDE) submissions to the U.S. Food and Drug Administration, FDA feedback, and the company’s use of pre-submission processes to refine its data on dosimetry, migration, and sterilization. Releases also describe international clinical activity, such as human trials conducted under U.S. regulatory standards and expansion efforts through Vivos Scientific India LLP.
Another major theme in Vivos news is the IsoPet animal therapy division. The company reports year-over-year growth in administered IsoPet therapies, case studies across dogs, cats, horses, and exotic animals, and certifications of new veterinary clinics, including equine and small animal hospitals. Updates often discuss clinical outcomes like equine ocular squamous cell carcinoma treatments without ocular damage, as well as subsidized case study programs intended to generate publishable data.
Additional RDGL coverage includes manufacturing and intellectual property developments, such as validation of an electron beam sterilization process under ISO 11137 and patent filings related to sterile thermogels and PrecisionGel agent-release characteristics. Vivos also issues news on strategic collaborations, notably with Exubrion Therapeutics, to coordinate clinic relationships and co-market IsoPet in equine oncology. For readers tracking the evolution of targeted radionuclide therapies and related medical devices, the Vivos Inc. news stream provides ongoing insight into clinical, regulatory, and operational progress.
Vivos Inc. (OTCQB: RDGL) has successfully completed its first IsoPet® therapy on a horse with a tumor at the University of Missouri. This marks an expansion of IsoPet® into the equine market, providing a unique treatment option for larger animals. The horse's tumor has already stopped growing post-treatment. Dr. Mike Korenko emphasized the importance of this development for the company's business strategy, aiming to further refine the technique and collaborate with a private clinic. Interested horse owners can now express their interest in the therapy via the company’s website.
Vivos Inc. (OTCQB: RDGL) has successfully extended its IsoPet® trademark protection internationally, confirmed by the U.S. Patent and Trademark Office. The isopet trademark is now registered with the World Intellectual Property Organization (WIPO) for veterinary isotopes. Countries like Australia, Canada, and the UK have 18 months to object to this registration. Dr. Korenko emphasized the significance of this development for Vivos' global branding mission in pet cancer treatment. The IsoPet® solution utilizes Yttrium-90 for targeted brachytherapy in animals and humans, indicating promising therapeutic advancements.
Vivos Inc. (OTCQB: RDGL) has enhanced its manufacturing processes for Radiogel™, crucial for FDA compliance in upcoming clinical trials. Key improvements include fifteen polymer runs and over fifty new Quality Management System documents, along with new precision process control equipment. These efforts aim to accelerate pre-clinical testing and strengthen IDE submission to the FDA, expected within 90-120 days. The company is also exploring contracts for international production of RadioGel™ and IsoPet®. CEO Korenko emphasized that these advancements make the company a serious contender in cancer treatment for both animals and humans.
Vivos Inc (RDGL) has announced its participation in the LD 500 investor conference, scheduled for September 3, 2020, at 1:40 PM PST. Dr. Mike Korenko, CEO, will present virtually, emphasizing the accessibility of this event amid COVID-19 restrictions. The conference runs from September 1 to 4, offering a platform for unique companies in the microcap space. Vivos specializes in an Yttrium-90 based injectable brachytherapy device for treating tumors in humans and animals, utilizing proprietary hydrogel technology for targeted radiation treatment.